| 產(chǎn)品編號 |
bs-4561R |
| 英文名稱 |
Bivalirudin Rabbit pAb
|
| 中文名稱 |
比伐盧定（水蛭素類似物）抗體 |
| 別 名 |
Bivalirudin; 128270-60-0 Hirudin |
| 產(chǎn)品類型 |
小分子抗體
|
| 研究領(lǐng)域 |
心血管 免疫學(xué) |
| 抗體來源 |
Rabbit |
| 克隆類型 |
Polyclonal
|
| 克 隆 號 |
|
| 交叉反應(yīng) |
(predicted: Hirudin)
|
| 產(chǎn)品應(yīng)用 |
IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ICC/IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 |
2.108 kDa |
| 檢測分子量 |
|
| 細(xì)胞定位 |
分泌型蛋白
|
| 性 狀 |
Liquid |
| 濃 度 |
1mg/ml |
| 免 疫 原 |
KLH conjugated synthetic peptide Bivalirudin (d-FPRPGGGGNGDFEEIPEEYL) |
| 亞 型 |
IgG |
| 純化方法 |
affinity purified by Protein A |
| 緩 沖 液 |
0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 |
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) |
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed |
PubMed |
| 產(chǎn)品介紹 |
Bivalirudin is a specific and reversible direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
|
|
|
